☆ 4.5 Article

Omission of Axillary Dissection in Node Positive Breast Cancer After Neoadjuvant Systemic Therapy

JOURNAL OF SURGICAL RESEARCH (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Omission of axillary lymph node dissection in patients with ypN plus breast cancer after neoadjuvant chemotherapy: A retrospective multicenter study (KROG 21-06)

Younghee Park et al.

Summary: This study evaluated the impact of omitting axillary lymph node dissection (ALND) on oncological outcomes in breast cancer patients with residual nodal disease after neoadjuvant chemotherapy (NAC). The results showed that performing only sentinel lymph node biopsy (SLNBx) without ALND in patients with residual nodal disease did not have a negative impact on disease-free survival (DFS) and overall survival (OS).

EJSO (2023)

添加到收藏夹

Article Oncology

Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients

Christina Yau et al.

Summary: This study analyzed data from multiple independent cohorts to evaluate the relationship between residual cancer burden (RCB) and long-term prognosis in different subtypes of breast cancer. The results showed that higher RCB score was significantly associated with worse event-free survival in all breast cancer subtypes. The study suggests considering the evaluation of RCB as part of standard pathology reporting.

LANCET ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Breast Cancer, Version 3.2022

William J. Gradishar et al.

Summary: This article discusses the complex therapeutic options for patients with noninvasive or invasive breast cancer, as well as the recommendations provided by the NCCN Clinical Practice Guidelines for Breast Cancer. It focuses on the overall management of ductal carcinoma in situ and the workup and locoregional management of early stage invasive breast cancer.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2022)

添加到收藏夹

Article Oncology

The Clinical Impact of Neoadjuvant Endocrine Treatment on Luminal-like Breast Cancers and Its Prognostic Significance: Results from a Single-Institution Prospective Cohort Study

Covadonga Marti et al.

Summary: This study evaluated the safety and effectiveness of neoadjuvant endocrine treatment (NET) in postmenopausal patients with luminal-like breast cancers. The results showed that NET effectively downstaged the tumors in terms of size and Ki67 proliferation rate, leading to a higher rate of breast-conserving surgery. Ki67 fold change after four weeks was related to the effectiveness of the treatment. NET was proven to be a safe and well-tolerated approach with potential prognostic value.

CURRENT ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Axillary Management After Neoadjuvant Endocrine Therapy for Hormone Receptor-Positive Breast Cancer

Olga Kantor et al.

Summary: For patients selected for NET, over 90% of cN0 patients have fewer than three positive nodes at surgery. There was no survival difference between SLNB and ALND in the DFBWCC cohort, indicating an opportunity to de-escalate axillary treatment in patients with limited residual nodal disease.

ANNALS OF SURGICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Nodal Recurrence in Patients With Node-Positive Breast Cancer Treated With Sentinel Node Biopsy Alone After Neoadjuvant Chemotherapy-A Rare Event

Andrea Barrio et al.

Summary: This study examined nodal recurrence rates in patients with clinically node-positive cancer treated with sentinel lymph node biopsy after neoadjuvant chemotherapy, showing low rates of axillary failure at a median follow-up of 40 months, supporting potential omission of axillary lymph node dissection in patients achieving nodal pathologic complete response with SLNB alone.

JAMA ONCOLOGY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Sentinel node biopsy alone for breast cancer patients with residual nodal disease after neoadjuvant chemotherapy

Jung Whan Chun et al.

Summary: This study analyzed the long-term outcomes of patients with residual N1 nodal disease following neoadjuvant chemotherapy for breast cancer and found that omission of axillary lymph node dissection using propensity score matching was oncologically safe. No significant differences in axillary recurrence-free survival, distant metastasis-free survival, overall survival, and breast cancer-free survival were observed between SLNB only group and ALND group after propensity score matching.

SCIENTIFIC REPORTS (2021)

添加到收藏夹

Article Oncology

Patterns of Failure in Women Who Have Residual Nodal Disease After Neoadjuvant Chemotherapy for Breast Cancer According to Extent of Lymph Node Surgery

Margaret M. Kozak et al.

CLINICAL BREAST CANCER (2020)

添加到收藏夹

Article Surgery

Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer Surgical Results From the BrighTNess Randomized Clinical Trial

Mehra Golshan et al.

JAMA SURGERY (2020)

添加到收藏夹

Article Oncology

Prognostic significance of residual nodal disease after neoadjuvant endocrine therapy for hormone receptor-positive breast cancer

Olga Kantor et al.

NPJ BREAST CANCER (2020)

添加到收藏夹

Article Oncology

Patterns of Axillary Management in Stages 2 and 3 Hormone Receptor-Positive Breast Cancer by Initial Treatment Approach

Anna Weiss et al.

ANNALS OF SURGICAL ONCOLOGY (2019)

添加到收藏夹

Article Medicine, General & Internal

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

G. von Minckwitz et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Medicine, General & Internal

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy

N. Masuda et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Oncology

Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection

Abigail S. Caudle et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

添加到收藏夹

Article Oncology

Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial

Mila Donker et al.

LANCET ONCOLOGY (2014)

添加到收藏夹

Article Surgery

The response to neoadjuvant chemotherapy predicts clinical outcome and increases breast conservation in advanced breast cancer

Philip M. Spanheimer et al.

AMERICAN JOURNAL OF SURGERY (2013)

添加到收藏夹

Article Medicine, General & Internal

Axillary Dissection vs No Axillary Dissection in Women With Invasive Breast Cancer and Sentinel Node Metastasis A Randomized Clinical Trial

Armando E. Giuliano et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)

添加到收藏夹

Article Oncology

The National Cancer Data Base: A powerful initiative to improve cancer care in the United States

Karl Y. Bilimoria et al.

ANNALS OF SURGICAL ONCOLOGY (2008)

添加到收藏夹

Article Oncology

Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons oncology Group trial Z0011

Anthony Lucci et al.

JOURNAL OF CLINICAL ONCOLOGY (2007)

添加到收藏夹

Article Oncology

Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: The ALMANAC trial

RE Mansel et al.

JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)

添加到收藏夹

Article Oncology

Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial

IE Smith et al.

JOURNAL OF CLINICAL ONCOLOGY (2005)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.